(Q42720284)

English

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia

scientific article published on 15 March 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Phase 2 study of the JAK kinase inhibitor ruxolitinib in patients with refractory leukemias, including postmyeloproliferative neoplasm acute myeloid leukemia (English)

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

0 references

1 reference

ChEBI release 2020-05-28

1 reference

based on heuristic

inferred from title

Hagop Kantarjian

13

object named as

Hagop M Kantarjian

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Alessandra Ferrajoli

8

object named as

Alessandra Ferrajoli

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

7

object named as

Stefan Faderl

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

3

object named as

Zeev Estrov

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Srdan Verstovsek

2

object named as

Srdan Verstovsek

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Jorge Eduardo Cortes

5

object named as

Jorge Cortes

1 reference

Europe PubMed Central

5 November 2017

PMC publication ID

14

object named as

Farhad Ravandi

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Gautam Borthakur

9

object named as

Gautam Borthakur

1 reference

Europe PubMed Central

5 November 2017

PMC publication ID

Alireza Eghtedar

1

object named as

Alireza Eghtedar

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

6

object named as

Carol Bivins

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

4

object named as

Jan Burger

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

11

object named as

Peggy A Scherle

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

author name string

Solly George

10

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Robert C Newton

12

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

language of work or name

0 references

publication date

15 March 2012

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

119

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

20

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

4614-4618

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

Safety and efficacy of INCB018424, a JAK1 and JAK2 inhibitor, in myelofibrosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Ruxolitinib, a selective JAK1 and JAK2 inhibitor for the treatment of myeloproliferative neoplasms and psoriasis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

A phase II study of 5-azacitidine for patients with primary and post-essential thrombocythemia/polycythemia vera myelofibrosis.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

JAK and MPL mutations in myeloid malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Efficacy of decitabine in the treatment of patients with chronic myelomonocytic leukemia (CMML).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

The JAK-STAT pathway: a therapeutic target in hematological malignancies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Janus kinase 2: a critical target in chronic myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Arf gene loss enhances oncogenicity and limits imatinib response in mouse models of Bcr-Abl-induced acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Expression of Jak2V617F causes a polycythemia vera-like disease with associated myelofibrosis in a murine bone marrow transplant model

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Constitutive activation of STAT transcription factors in acute myelogenous leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

STAT signaling in the pathogenesis and treatment of leukemias

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Src kinases and not JAKs activate STATs during IL-3 induced myeloid cell proliferation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

IL-10 inhibits macrophage activation and proliferation by distinct signaling mechanisms: evidence for Stat3-dependent and -independent pathways

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Suppression of interleukin-3-induced gene expression by a C-terminal truncated Stat5: role of Stat5 in proliferation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

27 May 2018

Treatment of progression of Philadelphia-negative myeloproliferative neoplasms to myelodysplastic syndrome or acute myeloid leukemia by azacitidine: a report on 54 cases on the behalf of the Groupe Francophone des Myelodysplasies (GFM).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

16 August 2018

A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

16 August 2018

Therapeutic options for patients with myelofibrosis in blast phase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

16 August 2018

Two routes to leukemic transformation after a JAK2 mutation-positive myeloproliferative neoplasm.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

16 August 2018

Mutation of JAK2 in the myeloproliferative disorders: timing, clonality studies, cytogenetic associations, and role in leukemic transformation.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

16 August 2018

Stat5 is essential for the myelo- and lymphoproliferative disease induced by TEL/JAK2

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

3 November 2018

Adaptive secretion of granulocyte-macrophage colony-stimulating factor (GM-CSF) mediates imatinib and nilotinib resistance in BCR/ABL+ progenitors via JAK-2/STAT-5 pathway activation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4081383

1 December 2018

Leukemic transformation in myelofibrosis with myeloid metaplasia: a single-institution experience with 91 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/22422826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia

1 reference

https://pubmed.ncbi.nlm.nih.gov/22422826

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1182/BLOOD-2011-12-400051

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

5 November 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q42720284&oldid=1967129611"